Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Captainblkon Jan 11, 2020 3:39pm
19 Views
Post# 30542666

RE:Time to Buy

RE:Time to Buy
MyKnight wrote: Everybody that followed this company for the last 2 year, knew that they didn't have any money, but this never stop Kaly. 

We didn't expect such incredible result for the phase 2, now our product is going to get money for the first time in their existence thru licences agreement in Europe... and this pretty soon.
So I expect an european pharmaceutical company to go with Kaly, not GW pharma, they don't have enough money to afford Kaly.

So you can watch the boat pass on a Cure(almost...) for GVHD or yo can short like the one that write bad info on Kaly.

This product save life, don't kid yourself this is going to be huge, and I don't mean only a 1$, who knows how big this is going to be...., I'm guessing that it will take the World Market for GVHD, which is over a Billions a years.... 

This position this company to a value beetween 3 - 10 Billions Dollars as soon as the licence starts.... Kaly know this and that's why they didn't go for the buyout that was to low for is real value...

You also have to realise that people with $, suffering from this will go to europe until FDA is done....

Do your math you won't see chance llike this often.


Bullboard Posts